Why Morgan Stanley Downgraded Gilead, Valeant & Regeneron
October 02, 2015 at 12:28 PM EDT
Political rhetoric over drug prices has been cooking for the better part of the last year. It has boiled over in recent weeks, thanks to Hilary Clinton’s Twitter account and House Democrats. In this environment, how do investors navigate drug stocks? Morgan Stanley analysts David Risinger, Matthew Harrison looked at its portfolio of drug stocks […]
